Quantcast

Latest Cancer immunotherapy Stories

2014-09-11 08:27:28

-Conference Call and Webcast on September 12, 2014 at 8:30 a.m. ET, 5:30 a.m. PT- MENLO PARK, Calif. and LONDON, Sept. 11, 2014 /PRNewswire/ -- CANCER RESEARCH UK and Cancer Research Technology (CRT), the charity's development and commercialisation arm, have reached an agreement with Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a biotechnology company in the emerging field of regenerative medicine, to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in...

2014-09-10 12:28:10

The Emergence of Keytruda--the First PD-1 Inhibitor Approved in the U.S.--is a Significant Milestone in Oncology, According to Decision Resources Group BURLINGTON, Mass., Sept. 10, 2014 /PRNewswire/ -- The recent approval of Merck & Co.'s Keytruda by the U.S. Food and Drug Administration for the treatment of malignant melanoma is a significant milestone for Merck & Co. and for the oncology immunotherapy drug market. Decision Resources Group anticipates the launch of Keytruda as the...

2014-09-04 16:27:07

Unique Multivalent WT1 Vaccine to be developed across hematological malignancies and solid tumors NEW YORK, Sept. 4, 2014 /PRNewswire/ -- SELLAS Life Sciences Group (SELLAS), a Swiss-based development-stage biopharmaceutical company today announced that it has signed an exclusive global collaboration and license agreement with Memorial Sloan Kettering Cancer Center (MSK) for the development, marketing, and commercialization of MSK's proprietary WT1 cancer vaccine. "This...

2014-08-25 08:27:12

Initial Closing is for $10 Million FREDERICK, Md., Aug. 25, 2014 /PRNewswire/ -- Vaccinogen, Inc., (OTC.QB: VGEN) a cancer immunotherapy development company, announced today that it completed the initial closing of a private placement of $80 million of units and common stock. Vaccinogen received gross proceeds of $10 million in this first closing. http://photos.prnewswire.com/prnvar/20140825/139089 Vaccinogen is preparing to start ACTIVE, a confirmatory Phase IIIb pivotal...

2014-08-19 12:28:17

SYDNEY, Aug. 19, 2014 /PRNewswire/ -- Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ("Prima", the "Company") today announced that the abstract entitled, "Trial evaluating overall survival in epithelial ovarian cancer (EOC) patients in second remission with an autologous dendritic cell therapy targeting mucin 1" has been accepted for a poster presentation at the Society for Immunotherapy of Cancer ("SITC") 29th Annual Meeting. The poster will be presented by Prima's...

2014-08-11 08:29:29

HPV Immune Therapy VGX-3100 to Advance into Phase III PLYMOUTH MEETING, Penn., Aug. 11, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013. Total operating expenses were $14.0 million and $26.3 million for the three and six months...

2014-08-11 08:29:09

Patented Technology Enables Accurate Delivery of a Chemotherapeutic Drug to Targeted Tumor Cells, Reducing Drug-related Toxicity without Sacrificing Therapeutic Impact SYDNEY, Aug. 11, 2014 /PRNewswire/ -- EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No....

2014-08-11 08:28:16

TAMPA, Fla., Aug. 11, 2014 /PRNewswire/ -- Morphogenesis Inc., the Tampa-based biotech company that developed the ImmuneFx(TM) cancer vaccine for dogs, cats and horses, announces that it has chosen Florida Veterinary Referral Center & 24-Hour Emergency Hospital in Estero, FL, as the newest exclusive provider of the ImmuneFx(TM) therapy process for companion animals. ImmuneFx(TM) primes and educates the pet's own immune system to recognize and kill cancer cells without harming...

2014-08-06 12:28:13

Study Correlates Immune Response with Improved Survival in Prostate Cancer Patients after Receiving the Antigen Express Novel Immunotherapeutic AE37 WORCESTER, Mass. and TORONTO, Aug. 6, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced publication of a follow-up study from a Phase I clinical trial of the immunotherapeutic agent AE37 in patients with prostate cancer. The study demonstrates an association between a specific immune...

2014-07-16 04:21:39

TUEBINGEN, Germany, July 16, 2014 /PRNewswire/ -- Funds will be used to complete phase 3 study with IMA901 and to invest in the expansion of immatics' Human Immunopeptidome Program to identify the most relevant targets for cancer immunotherapies immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company leading the development of advanced immunotherapies that are active against cancer, today announces that it has...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.